PubRank

Antonio Sacco

Author PubWeight™ 44.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009 3.37
2 Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012 2.35
3 BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013 2.34
4 MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009 2.28
5 microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood 2008 2.10
6 P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2011 1.77
7 Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010 1.71
8 Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009 1.57
9 LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012 1.42
10 Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2009 1.40
11 RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009 1.39
12 Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008 1.36
13 SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008 1.24
14 Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012 1.23
15 Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008 1.16
16 Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010 1.16
17 Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2008 1.15
18 microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010 1.11
19 Defining the role of TORC1/2 in multiple myeloma. Blood 2011 1.10
20 Studying ancient crop provenance: implications from δ(13)C and δ(15)N values of charred barley in a Middle Bronze Age silo at Ebla(NW Syria). Rapid Commun Mass Spectrom 2012 1.09
21 Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res 2008 0.97
22 The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol 2008 0.91
23 Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res 2011 0.90
24 FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res 2011 0.90
25 Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2008 0.85
26 Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2007 0.83
27 Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res 2009 0.82
28 Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS One 2013 0.82
29 Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Clin Cancer Res 2012 0.78
30 Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.76
31 Role of proteasome inhibition in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009 0.76
32 Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Am J Hematol 2014 0.76
33 The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol 2011 0.75
34 Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet 2013 0.75
35 Novel therapeutic agents in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009 0.75
36 The role of miRNAs in plasma cell dyscrasias. Microrna 2014 0.75
37 Chemometric classification of Apulian and Slovenian wines using 1H NMR and ICP-OES together with HPICE data. J Agric Food Chem 2003 0.75
38 The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.75